首页> 外文期刊>ASSAY and Drug Development Technologies >Bioassays for Estrogenic Activity: Development and Validation of Estrogen Receptor (ERα/ERβ) and Breast Cancer Proliferation Bioassays to Measure Serum Estrogenic Activity in Clinical Studies
【24h】

Bioassays for Estrogenic Activity: Development and Validation of Estrogen Receptor (ERα/ERβ) and Breast Cancer Proliferation Bioassays to Measure Serum Estrogenic Activity in Clinical Studies

机译:雌激素活性的生物测定:雌激素受体(ERα/ERβ)和乳腺癌增殖生物测定的发展和验证,以在临床研究中测量血清雌激素活性

获取原文
获取原文并翻译 | 示例
       

摘要

Standard estrogenic prodrugs such as estradiol valerate (E2V) and increasingly popular phytoestrogen formulations are commonly prescribed to improve menopausal health. These drugs are metabolized to numerous bioactive compounds, known or unknown, which may exert combinatorial estrogenic effects in vivo. The aim of this study is to develop and validate estrogen receptor (ER) α/ERβ reporter gene and MCF-7 breast cancer cell proliferation bioassays to quantify serum estrogenic activities in a clinical trial setting. We measured changes in serum estrogenicity following ingestion of E2V and compared this to mass spectrometric measurements of its bioactive metabolites, estrone and 17β-stradiol. ERα bioactivity of the 192 serum samples correlated well (R = 79%) with 17β-estradiol levels, and adding estrone improved R to 0.83 (likelihood ratio test, P < 0.0001), suggesting that the ERα assay reflects summated activity of compounds in serum. ERβ correlated moderately (R = 0.52) with estrone and 17β-estradiol, with an estrone/17β-estradiol coefficient ratio that was twice that of ERα, indicating estrone was more active on a molar basis in the ERβ assay. Unlike the ERα and ERβ bioassays, MCF-7 cell proliferation was driven by 17β-estradiol, and addition of estrone did not increase the predictive value of the model, suggesting that the driver or drivers for breast cancer cell proliferation were not the same as for ERα and ERβ transactivation. In contrast, a decoction of the traditional Chinese medicinal herb Epimedium pubescens did not induce significant changes in estrogenic bioactivity over baseline. These data indicate that ERα/ERβ reporter gene and MCF-7 breast cancer cell proliferation bioassays reflect different aspects of estrogenic activity and that these assays suggest that the Epimedium formulation tested is unlikely to exert significant estrogenic effects in humans.
机译:通常规定使用标准雌激素前药,例如戊酸雌二醇(E2V)和日益流行的植物雌激素制剂,以改善更年期的健康状况。这些药物被代谢为许多已知或未知的生物活性化合物,它们可能在体内发挥组合雌激素作用。这项研究的目的是开发和验证雌激素受体(ER)α/ERβ报告基因和MCF-7乳腺癌细胞增殖生物测定法,以在临床试验中量化血清雌激素活性。我们测量了摄入E2V后血清雌激素的变化,并将其与质谱法测量的生物活性代谢物,雌酮和17β-雌二醇进行了比较。 192个血清样品的ERα生物活性与17β-雌二醇水平密切相关(R = 79%),并且添加雌酮使R值提高至0.83(似然比检验,P <0.0001),这表明ERα测定反映了血清中化合物的总活性。 ERβ与雌酮和17β-雌二醇呈适度相关性(R = 0.52),其雌酮/17β-雌二醇系数比是ERα的两倍,表明雌二醇在ERβ测定中的摩尔活性更高。与ERα和ERβ生物测定不同,MCF-7细胞的增殖是由17β-雌二醇驱动的,并且添加雌酮并没有增加模型的预测价值,这表明一个或多个乳腺癌细胞增殖的驱动因素与ERα和ERβ反式激活。相比之下,传统中药淫羊a汤未引起雌激素生物活性超过基线的显着变化。这些数据表明ERα/ERβ报告基因和MCF-7乳腺癌细胞增殖生物测定法反映了雌激素活性的不同方面,并且这些测定法表明所测试的淫羊med制剂不太可能对人类产生明显的雌激素作用。

著录项

  • 来源
    《ASSAY and Drug Development Technologies》 |2009年第1期|80-89|共10页
  • 作者单位

    Departments of Obstetrics & Gynecology;

    Departments of Medicine, National University of Singapore, National University Hospital, Yong Loo Lin School of Medicine, Republic of Singapore.;

    Departments of Obstetrics & Gynecology;

    Departments of Obstetrics & Gynecology;

    Departments of Obstetrics & Gynecology;

    Lilly-National University of Singapore Center for Clinical Pharmacology, Republic of Singapore.;

    Departments of Obstetrics & Gynecology;

  • 收录信息
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号